Monoclonal antibody of feline infectious peritonitis virus as well as preparation method and application of monoclonal antibody
By developing monoclonal antibodies to cat infectious peritonitis virus and their preparation methods, the problem of lack of special drugs has been solved, and an efficient treatment plan has been provided, which has significantly improved the cure rate of infectious peritonitis in cats.
Patent Information
- Application Number
- CN202310586476.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Currently, there is a lack of effective drugs for feline infectious peritonitis virus (FIPV), and clinical treatment mainly relies on symptomatic and supportive treatment.
A monoclonal antibody of cat infectious peritonitis virus and its preparation method was developed. The antibody was prepared and purified by the hybridoma cell line CGMCC NO.45347. .
The obtained monoclonal antibodies have high purity, specificity and high neutralization titer, which can effectively cure infectious peritonitis caused by FIPV and improve the treatment conditions of cats.
Smart Images

Figure CN119020299A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicines, and specifically relates to a feline infectious peritonitis virus monoclonal antibody and a preparation method and application thereof. Background Art
[0002] Feline infectious peritonitis (FIP) is a chronic, progressive, and fatal infectious disease caused by feline coronavirus (FCoV). FCoV is a non-segmented, single-stranded positive-strand RNA virus. The virus particles are spirally symmetrical and have an envelope. The surface of the envelope has petal-like fibrils, which appear corona-shaped under an electron microscope and are about 80 to 120 nm in diameter. The total length of the viral genome is about 30 kb, including 11 ORFs, encoding 4 structural proteins (S, M, E, and N) and 7 non-structural proteins (replicase proteins 1a and 1b, and auxiliary proteins 3a, 3b, 3c, 7a, and 7b). FCoV is divided into two biotypes: feline enteric coronavirus (FECV) and feline infectious peritonitis virus (FIPV). The two are identical in morphology and antigenicity, but very different in biological characteristics.
[0003] The initial symptoms of FIP are not obvious, with symptoms such as loss of appetite, depression, weight loss, dehydration, diarrhea, and persistent fever. The later symptoms are mainly divided into two types: exudative or non-exudative. The exudative type (accounting for 60% to 70% of FIP pathology) is manifested as abdominal distension due to high-protein exudate in the chest and abdominal cavity after about 1 month. The abdomen is painless when palpated, and there is a significant sense of fluctuation. In addition to general symptoms such as persistent fever and loss of appetite for more than 2 weeks, the non-exudative type usually has different clinical symptoms depending on the location of the FIP lesion. The most common manifestations are mainly infringements of the eyes, central nervous system, kidneys, and liver, and there is almost no pleural effusion in the chest. Cats of different ages can be infected, and the incidence rate is high in elderly cats and cats under 1 year old.
[0004] At present, there is no effective vaccine or specific therapeutic drug in the world. Clinical treatment mainly combines symptomatic and supportive treatment. There is an urgent need for a specific drug to treat FIP infection. Summary of the invention
[0005] In order to solve the technical problem in the above background technology that there is no specific drug for FIP on the market, the present invention provides a feline infectious peritonitis virus monoclonal antibody and a preparation method and use thereof.
[0006] The technical solution adopted by the present invention is as follows:
[0007] On one hand, the present invention provides a hybridoma cell strain capable of secreting monoclonal antibodies against feline infectious peritonitis virus. The accession number of the hybridoma cell strain is CGMCC NO.45347, and the deposit address is the General Microbiology Center of China National Committee for the Administration of Microbiological Culture Collection.
[0008] The beneficial effects of the present invention are as follows: the hybridoma cells of the present invention can stably secrete monoclonal antibodies against feline infectious peritonitis virus, cure feline infectious peritonitis caused by FIPV, and improve the treatment conditions of cats, thereby solving the technical problem that there is no specific drug for feline infectious peritonitis on the market.
[0009] Another aspect of the present invention provides a feline infectious peritonitis virus monoclonal antibody secreted by the hybridoma cell line described above.
[0010] The invention has the beneficial effects that the feline infectious peritonitis virus monoclonal antibody of the invention has high purity, good specificity and good neutralization titer.
[0011] Another aspect of the present invention provides a method for preparing the feline infectious peritonitis virus monoclonal antibody as described above, comprising the following steps:
[0012] S1, purifying the feline infectious peritonitis virus BJD58 strain and immunizing mice, taking spleen cells of the immunized mice and fusing them with mouse myeloma cells to obtain fusion cells;
[0013] S2. The fused cells in step S1 are subjected to antibody detection by ELISA method, and cells with positive detection results are the desired hybridoma cells. Then, the hybridoma cells are cloned by limited dilution cloning method and the cell supernatant positivity reaches 100%. Then, the hybridoma cells with positive screening results are expanded and cultured or ascites induction method in syngeneic mice is used to obtain feline infectious peritonitis virus monoclonal antibodies.
[0014] The beneficial effect of the present invention is that the preparation method can effectively obtain hybridoma cells, thereby preparing and obtaining feline infectious peritonitis virus monoclonal antibodies in large quantities, thereby improving the success rate and yield of feline infectious peritonitis virus monoclonal antibodies.
[0015] Based on the above technical solution, the present invention can also be improved as follows.
[0016] Furthermore, in step S1, the mice are immunized at least once during the process of immunizing the mice with the purified feline infectious peritonitis virus BJD58 strain.
[0017] Furthermore, the mice are immunized at least three times during the process of immunizing the mice with the purified feline infectious peritonitis virus BJD58 strain.
[0018] Furthermore, the expansion culture method is: using a bioreactor fermentation culture method to culture the hybridoma cells in large quantities, then collecting the cultured hybridoma cells and centrifuging them to take the supernatant or ultrafiltration and concentrating the collected cell supernatant;
[0019] The method of inducing ascites in syngeneic mice is as follows: BALB / c mice weighing more than 20g are selected, and 0.5mL of sterilized liquid paraffin is injected into the peritoneal cavity of each mouse; after 14 to 18 days, hybridoma cells are inoculated into the peritoneal cavity of the mouse; starting from the 7th day after the cell implantation, the abdomen of the mouse is observed every day, and when the abdomen of the mouse is obviously swollen, the abdominal cavity is punctured with a 9# needle to collect ascites, and the ascites is centrifuged at 3000r / min for 10min to remove fat and precipitation, and the supernatant is collected.
[0020] Another aspect of the present invention provides a pharmaceutical composition, which comprises the feline infectious peritonitis virus monoclonal antibody as described above and a pharmaceutically acceptable carrier and / or excipient.
[0021] Another aspect of the present invention also provides the use of the above-mentioned feline infectious peritonitis virus monoclonal antibody in the preparation of a medical detection preparation, wherein the medical detection preparation is an immunohistochemistry detection preparation, an immunofluorescence detection preparation, an immunoblotting reaction detection preparation or an immunoprecipitation detection preparation.
[0022] Another aspect of the present invention provides a kit for detecting feline infectious peritonitis virus, comprising the feline infectious peritonitis virus monoclonal antibody as described above.
[0023] Another aspect of the present invention also provides the use of the above-mentioned feline infectious peritonitis virus monoclonal antibody in the preparation of a drug for treating feline infectious peritonitis infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 The SDS-PAGE electrophoretogram in Example 1 of the present invention is shown; DETAILED DESCRIPTION
[0025] I. Relevant Definitions
[0026] According to the above contents of the present disclosure, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present disclosure, other various forms of modifications, replacements or changes may be made.
[0027] Drug or drug composition
[0028] The feline infectious peritonitis virus disclosed in the present invention, together with one or more excipients such as adjuvants, carriers or diluents, can be placed in the form of pharmaceutical compositions, unit dosages or dosage forms. The pharmaceutical composition can be in a solid dosage form (such as a powder, granules, pellets, coated or uncoated tablets or filled capsules) or a liquid dosage form (such as a solution, suspension, emulsion or a capsule filled therein) or a semisolid dosage form (such as a gel, cream and ointment). The dissolution and release characteristics of one or more active ingredients of the pharmaceutical dosage form can vary in the range of seconds to months.
[0029] The "drug" or "pharmaceutical composition" is designed for use in mice and humans and can be administered via all routes of administration. Preferred routes of administration are injection, oral, pulmonary, nasal, rectal, and parenteral. Such pharmaceutical compositions and unit dosage forms thereof may contain conventional or novel ingredients in conventional or special proportions, with or without additional active compounds or ingredients, and such unit dosage forms may contain any suitable effective amount of active ingredients to be employed commensurate with the intended daily dosage range.
[0030] The term "carrier" as applied to the pharmaceutical compositions of the present disclosure relates to a diluent, adjuvant or excipient with which the active compound is administered.
[0031] Methods of treatment and pharmaceutical formulations
[0032] Whether by oral, injection, rectal or parenteral (including intravenous and subcutaneous) or in some cases even topical routes, the feline infectious peritonitis virus of the present disclosure or with one or more pharmaceutically-acceptable excipients, carriers or diluents, particularly and preferably in the form of their pharmaceutical compositions, can be administered in an effective amount to a subject in need thereof, such as a living mouse (including a human) body, for the treatment, alleviation or improvement, relief or elimination of indications or conditions susceptible thereto or indications or conditions described elsewhere in the present disclosure.
[0033] The term "treatment" as used herein means to alleviate or relieve at least one symptom of a disease in a subject. Within the meaning of the present disclosure, the term "treatment" also refers to inhibiting, delaying the onset (i.e., the pre-clinical manifestation of the disease) and / or reducing the risk of developing or worsening the disease.
[0034] The medicaments or pharmaceutical compositions of the present disclosure can be administered orally, topically, parenterally or mucosally (e.g., buccally, by inhalation or rectally) in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers. It is generally desirable to use the oral route. The active agent can be administered orally in the form of capsules, tablets, etc. (see Remington: The Science and Practice of Pharmacy, 20th Edition).
[0035] For oral administration in the form of tablets or capsules, the active drug component can be mixed with non-toxic, pharmaceutically acceptable excipients such as binders (e.g., pregelatinized corn starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, sucrose, glucose, mannitol, sorbitol and other reducing and non-reducing sugars, microcrystalline cellulose, calcium sulfate or dibasic calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica, stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, etc.); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate), coloring and flavoring agents, gelatin, sweeteners, natural and synthetic gums (such as acacia, tragacanth or alginates), buffer salts, carboxymethylcellulose, polyethylene glycol, waxes, and the like. For oral administration in liquid form, the drug component can be combined with a non-toxic, pharmaceutically acceptable inert carrier (e.g., ethanol, glycerol, water), an anti-settling agent (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats), an emulsifier (e.g., lecithin or gum arabic), a non-aqueous carrier (e.g., almond oil, oily esters, ethanol or fractionated vegetable oils), a preservative (e.g., methyl or propyl p-hydroxybenzoate or sorbic acid), etc. Stabilizers such as antioxidants (BHA, BHT, propyl citric acid, sodium ascorbate, citric acid) can also be added to stabilize the dosage form.
[0036] The medicine or pharmaceutical composition of the present disclosure can be delivered parenterally, that is, administered intravenously (iv), intracerebroventricularly (icv), subcutaneously (sc), intraperitoneally (ip), intramuscularly (im), subcutaneously (sd) or intradermally (id), by direct injection, for example, by bolus injection or continuous infusion. The formulation for injection can be presented in unit dosage form, for example, in an ampoule or multi-dose container with an added preservative. The composition can be in the shape of an excipient, in the form of a suspension, solution or emulsion in an oil or aqueous vehicle, and can include formulation agents such as anti-settling agents, stabilizers and / or dispersants. Alternatively, the active ingredient can be reconstituted with a suitable carrier (e.g., sterile pyrogen-free water) before use in powder form.
[0037] The medicaments or pharmaceutical compositions of the present disclosure may also be formulated for rectal administration, for example, as suppositories or retention enemas (eg, containing conventional suppository bases such as cocoa butter or other glycerides).
[0038] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The examples given are only used to explain the present invention and are not used to limit the scope of the present invention.
[0039] Embodiment 1,
[0040] A method for preparing a feline infectious peritonitis virus monoclonal antibody comprises the following steps:
[0041] S1, purifying the feline infectious peritonitis virus BJD58 strain and immunizing mice, taking spleen cells of the immunized mice and fusing them with mouse myeloma cells to obtain fusion cells;
[0042] S2. The fused cells in step S1 are subjected to antibody detection by ELISA method, and cells with positive detection results are the desired hybridoma cells. Then, the hybridoma cells are cloned by limited dilution cloning method and the cell supernatant positivity reaches 100%. Then, the hybridoma cells with positive screening results are expanded and cultured or ascites induction method in syngeneic mice is used to obtain feline infectious peritonitis virus monoclonal antibodies.
[0043] Specifically, the hybridoma cells and feline infectious peritonitis virus monoclonal antibodies are prepared by the following steps:
[0044] 1. Preparation and biological characteristics of feline infectious peritonitis virus monoclonal antibodies
[0045] 1. Materials
[0046] 1.1. Toxins
[0047] The feline infectious peritonitis virus BJD58 strain was isolated, identified and preserved by Sino-Swiss Animal Inspection (Beijing) Biotechnology Co., Ltd.; the feline parvovirus HBX05 strain, feline herpesvirus BJS01 strain and feline calicivirus BJH13 strain were isolated, identified and preserved by Beijing Broadly Biotechnology Co., Ltd.
[0048] 1.2 Cells
[0049] SP2 / 0 myeloma cells, CRFK cells and F81 cells were passaged and stored by Beijing Broadly Biotechnology Co., Ltd.
[0050] 1.3 Reagents
[0051] DMEM culture medium was purchased from Gibco; bovine serum was purchased from Lanzhou Minhai Bioengineering Co., Ltd.; viral genome DNA / RNA extraction kit and RNA reverse transcription kit were purchased from Beijing Quanshijin Biotechnology Co., Ltd.; PCR and RT-PCR amplification kits were purchased from Bao Bioengineering (Dalian) Co., Ltd.; Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), polyethylene glycol fusion agent (PEG 2000), HAT, HT culture medium, and mouse monoclonal antibody typing kit were purchased from Sigma; horseradish peroxidase-labeled goat anti-mouse IgG (H+L) was purchased from Shanghai Biyuntian Biotechnology Co., Ltd.; Protein A Antibody Purification Kit was purchased from abcam; and BCA protein concentration determination kit was purchased from Beijing Solebow Technology Co., Ltd.
[0052] 1.4 Experimental Animals
[0053] Female BALB / c mice were purchased from Sibeifu Biotechnology Co., Ltd. (Beijing).
[0054] 2. Methods
[0055] 2.1. Preparation of hybridoma cells
[0056] 2.1.1 Antigen preparation
[0057] 2.1.1.1. Preparation of Feline Infectious Peritonitis Virus Solution
[0058] The BJD58 strain of feline infectious peritonitis virus was inoculated into CRFK cells, cultured and observed in an incubator at 37°C and 5% CO2, harvested when the cell pathological rate reached about 80%, frozen and thawed twice, and the virus solution was harvested and stored at -70°C for later use.
[0059] 2.1.1.2 Virus purification
[0060] The virus solution was centrifuged at 4°C, 8000 r / min for 30 minutes to remove cell debris, and the supernatant of the virus solution was collected and ultracentrifuged at 40000 r / min for 3 hours to collect the precipitate, which was resuspended in 1% of the original volume of PBS for later use.
[0061] Prepare sucrose solutions with mass concentrations of 60%, 50%, 40%, 30% and 20%, add them to 5 ml centrifuge tubes from bottom to top, add 0.8 ml of each sucrose concentration, and finally add 1 ml of resuspended virus. Ultracentrifuge at 40000 r / min at 4°C for 3 h, collect the purified virus bands as antigens, and store them at -70°C for later use; calculate TCID50 according to the Reed-Muench method, and determine the protein content according to the BCA method.
[0062] 2.1.2. Mouse immunization
[0063] Ten female BALB / c mice aged 6 to 8 weeks were selected. An appropriate amount of purified FIPV BJD58 strain was diluted to 1 mg / ml with PBS, emulsified with an equal volume of Freund's complete adjuvant, and injected intraperitoneally, 0.3 ml / mouse; in the second and fourth weeks after the first immunization, the purified virus was emulsified with an equal volume of Freund's incomplete adjuvant for the second and third immunizations, respectively; after the third immunization, blood was collected weekly to measure the serum titer by ELISA method. When the ELISA titer reached 1:8000 or above, FIPV BJD58 strain diluted to 1 mg / ml was injected into mice for booster immunization, 0.15 ml / mouse; 3 days later, the spleen of the mice was taken for fusion.
[0064] 2.1.3 Cell Fusion
[0065] 2.1.3.1. Preparation of spleen cells from immunized mice
[0066] On the third day after booster immunization, the spleen of the immunized mouse was aseptically removed, placed in a plate containing DMEM culture medium, and gently rinsed to remove attached connective tissue and fat; the spleen was chopped with scissors and placed on a 200-mesh copper grid, the spleen was ground with the inner core of a syringe, and rinsed with DMEM culture medium so that all spleen cells passed through the mesh and entered the solution, the spleen cell solution was transferred to a centrifuge tube, centrifuged at 1000r / min for 5 minutes, and the supernatant was discarded; the cells were centrifuged and washed once in the same way; the cells were then resuspended in DMEM culture medium, the above cell suspension was taken to obtain spleen cells of immunized mice, and they were counted and set aside.
[0067] 2.1.3.2 Preparation of SP2 / 0 myeloma cells
[0068] 36-48 hours before fusion, SP2 / 0 cells were divided into bottles and expanded and cultured in 75cm 2 On the day of fusion, select SP2 / 0 cells with good morphology and logarithmic growth, gently blow them off the flask wall, collect them in a centrifuge tube, centrifuge at 1000r / min for 5 minutes, and then resuspend them with an appropriate amount of DMEM medium for cell fusion.
[0069] 2.1.3.3 Preparation of feeder cells
[0070] On the day of cell fusion, blood was collected from the eyeballs of unimmunized BALB / c mice (8-12 weeks old), and the mice were killed by cervical dislocation and soaked in 75% alcohol for 5 minutes. The mice were placed in a wax tray on a clean bench and fixed with the abdomen facing upward. The skin of the BALB / c mice was lifted with sterilized tweezers, and the abdominal skin was carefully cut open to separate the skin and peritoneum to fully expose the peritoneum. An appropriate amount of DMEM culture medium was injected into the abdominal cavity with a sterile syringe. After the abdomen was massaged and fully mixed, the intraperitoneal fluid was extracted and added to a sterile centrifuge tube, and the washing was repeated 2-3 times. The obtained liquid was centrifuged at 1000r / min for 5 minutes, and the supernatant was discarded. An appropriate amount of DMEM culture medium was added to the precipitate, and the cells were resuspended. After counting the above cell suspension, the cells were suspended with culture medium containing HAT to adjust the cell concentration to 1-2×10 5 / ml, added into 96-well cell culture plate (100 μl / well), and placed in a 37°C, 5% CO2 incubator for culture until use.
[0071] 2.1.3.4 Cell Fusion
[0072] The spleen cells of the immunized mice and the SP2 / 0 cells in the logarithmic growth phase were mixed in a centrifuge tube at a ratio of 5 to 10:1, centrifuged at 1000 r / min for 8 minutes, the supernatant was discarded, and the bottom of the tube was gently tapped to make the precipitated cells loose and uniform into a paste; 1 ml of 50% PEG 2000 (pH 8.0) solution preheated to 37°C was slowly dripped in for fusion; 25 ml of DMEM culture medium was added to the centrifuge tube to terminate the fusion effect; the fused cell solution was centrifuged at 1000 r / min for 5 minutes, the supernatant was discarded, and the cells were resuspended in a HAT culture medium preheated in a 37°C water bath; the cells were added to a 96-well culture plate with feeder cells, 100 μl / well, and cultured in an incubator at 37°C and 5% CO2. The cell growth was recorded daily, and on the 4th day after fusion, the medium was replaced by half of 1% HAT selection culture medium, and on about 7 to 10 days, the medium was replaced by half of 1% HT selection culture medium for continued culture.
[0073] 2.1.4 Cloning of positive hybridoma cells
[0074] After half-volume medium replacement, observe the growth of cells every day. When the cell colonies grow to 1 / 3 of the bottom of the well, take the cell supernatant and perform antibody detection by ELISA. If the test result is positive for hybridoma cells, use the limiting dilution cloning method to clone the hybridoma cells in time. The specific method is as follows:
[0075] (1) Prepare feeder cells one day in advance.
[0076] (2) Select cells that are in good condition and are single-cell colonies for cloning. Use a pipette to transfer the cells to a new 24-well cell culture plate and wash them as clean as possible.
[0077] (3) After counting, one cell was plated per well and added to a 96-well cell culture plate for culture.
[0078] (4) Observe the cells. When the cells cover 1 / 3 of the bottom of the well, perform ELISA on the cell supernatant to detect whether there are specific antibodies in the supernatant, and mark the corresponding cell wells to detect their positive rate.
[0079] (5) For the positive wells with good antibody secretion and single cell colony status, the same method is used to perform the next subcloning. In order to avoid cell contamination, the cells after each cloning should be frozen in time.
[0080] (6) After three clonings, if the positive rate of the cell supernatant reaches 100%, it can be determined that the positive hybridoma cell line can stably secrete monoclonal antibodies. If it does not reach 100%, cloning should be continued until the positive rate reaches 100%, and the positive wells should be expanded and cultured.
[0081] 2.2. Large-scale preparation and purification of monoclonal antibodies
[0082] The screened positive hybridoma cell lines are used for the preparation of monoclonal antibodies by expanding culture or inducing ascites in syngeneic mice.
[0083] Preparation of monoclonal antibodies by cell expansion culture method: hybridoma cells are cultured in large quantities by bioreactor fermentation culture method, the cultured hybridoma cell supernatant is collected, centrifuged at 3000r / min for 10min, and the supernatant is taken or the collected cell supernatant is concentrated by ultrafiltration.
[0084] Preparation of ascites of syngeneic mouse monoclonal antibodies: BALB / c mice weighing more than 20 g (8-10 weeks old) were selected, and 0.5 mL of sterilized liquid paraffin was injected into the peritoneal cavity of each mouse; 14-18 days later, hybridoma cells (0.5-1×10 6 cells / mouse); starting from the 7th day after cell implantation, observe the abdomen of the mouse every day, and when the abdomen of the mouse is obviously swollen, # The abdominal cavity is punctured with a needle to collect ascites, which can usually be collected 3 to 5 times in a row. The ascites is centrifuged at 3000r / min for 10min to remove oil and precipitate, and the supernatant is collected to measure the antibody titer.
[0085] Purification: Purify according to the instructions of "Protein A Antibody Purification Kit". After purification, dialyze the solution in a dialysis bag with a molecular weight cutoff of 30kDa, and dialyze the purified antibody into PBS.
[0086] 2.3. Determination of monoclonal antibody secretion stability
[0087] The hybridoma cells were continuously passaged to the P20 generation and frozen in liquid nitrogen for 3, 6, 9, and 12 months before being revived. When the cells were fully grown, the culture medium was centrifuged and the supernatant was taken for determination according to the "Neutralization Test Method" in the appendix of the current "Chinese Pharmacopoeia of Veterinary Medicine".
[0088] 2.4. Identification of biological characteristics of monoclonal antibodies
[0089] 2.4.1. Identification of monoclonal antibody subtypes
[0090] Identify according to the "Mouse Monoclonal Antibody Identification Kit Instructions".
[0091] 2.4.2. Specificity identification of monoclonal antibodies
[0092] Feline infectious peritonitis virus (BJD58 strain), feline parvovirus (HBX05 strain), feline herpes virus (BJS01 strain), and feline calicivirus (BJH13 strain) were diluted to 200 TCID50 / 0.1 ml with DMEM cell culture medium containing 4% bovine serum, mixed with an equal volume of monoclonal antibody secreted by 3C1 cells, neutralized at 37°C for 1 hour, and inoculated into 96-well cell culture plates (samples neutralized with FIPV and FHV: inoculated into CR wells that have grown into a monolayer) On FK cells; samples neutralized with FPV: 100μl of F81 cell suspension containing 2% bovine serum was added to each well; ③ samples neutralized with FCV: inoculated on F81 cells that have grown into a monolayer), each sample was inoculated into 4 wells, 100μl in each well; at the same time, normal cell control and virus control (virus (200TCID50 / 0.1ml) was mixed with DMEM culture medium in equal volumes and neutralized at 37℃ for 1 hour) were set up in 4 wells each; cultured in an incubator at 37℃ and 5% CO2 and observed for 4 to 7 days.
[0093] 2.4.4 Analysis of chromosome number in hybridoma cells
[0094] Take the hybridoma cells in the logarithmic growth phase, add colchicine at 0.1 μg / ml to the culture medium, and continue to culture in a 37°C, 5% CO2 cell culture incubator for 6 to 10 hours; after blowing the cells with DMEM culture medium, centrifuge at 1000r / min for 10 minutes, discard the supernatant, and add 5ml of 0.075mol / L preheated at 37°C KCl solution, mix by blowing, and place at 37°C for 30 minutes; add 1 ml of freshly prepared acetic acid: methanol (1:3) fixative to the cell suspension, mix by blowing, and slightly fix the cell surface to prevent the cells from sticking together; centrifuge at 1000r / min for 10 minutes, discard the supernatant, add 5-10 ml of fixative, gently blow evenly, and let stand at room temperature for 30 minutes, repeat this fixation 3 times, and finally add 5 ml of fixative to suspend the cells and mix, and let stand at 4°C overnight; the next day, discard part of the supernatant, add 0.5-1 ml of fixative, resuspend the cells by blowing, add 1-2 drops of cell suspension on a pre-cooled slide, and dry at room temperature; after staining with Giemsa staining solution, select cells with well-dispersed chromosomes, no overlap, and no scattered chromosomes for observation and analysis under a microscope, and record their chromosome numbers.
[0095] 2.4.5. Identification of Monoclonal Antibody Purity
[0096] The purity of the purified monoclonal antibody was identified by SDS-PAGE.
[0097] 3. Results
[0098] 3.1. Determination of virus content and protein content after purification
[0099] After the BJD58 virus liquid was purified, the virus content was 10 6.0 TCID 50 / ml. The protein content was determined by BCA method, and the purified virus protein content was 3.1mg / ml.
[0100] 3.2. Screening results of positive hybridoma cell lines
[0101] After the spleen cells of the immunized mice were fused with the hybridoma cells, a hybridoma cell line that stably secreted anti-FHV monoclonal antibodies was obtained through HAT / HT selection culture, screening, identification and subcloning, and was named 3C1. It was deposited with strains and a deposit certificate was obtained. The deposit number of the hybridoma cell line is CGMCC NO.45347, and the deposit address is the General Microbiology Center of the China Microbiological Culture Collection Administration.
[0102] 3.3 Results of monoclonal antibody secretion stability test
[0103] The supernatants of hybridoma cells of generations P5, P10, P15, and P20 and the supernatants of hybridoma cells frozen in liquid nitrogen for 3, 6, 9, and 12 months and then revived were taken for neutralization titer determination. The results showed that the neutralization titer of hybridoma cells was 1:159-178 when they were continuously passed to generation P20, and the antibody titer of 3C1P20 was 1:126-159 when they were stored in liquid nitrogen for 12 months, indicating that the antibody secretion of hybridoma cells was stable. The results are shown in Tables 1 and 2.
[0104] Table 1 Neutralization titer determination results of hybridoma cell supernatants of different generations
[0105]
[0106] Table 2 Neutralization titer determination results of hybridoma cell supernatants of 3C1 P20 generation stored in liquid nitrogen for different time periods
[0107]
[0108] 3.4 Monoclonal Antibodies and Subclass Identification Results
[0109] The subtype of monoclonal antibody 3C1 was IgG2b as determined by mouse monoclonal antibody typing kit (see Table 3).
[0110] Table 3 Results of monoclonal antibody subclass identification
[0111] Cell lines IgG1 IgG2a IgG2b IgG3 IgM 3C1 0.109 0.135 1.161 0.087 0.156
[0112] 3.5 Monoclonal Antibody Specificity Identification Results
[0113] The monoclonal antibody secreted by 3C1 cells showed no CPE in the FIPV neutralization wells, but showed CPE in the FPV, FHV and FCV neutralization wells; no CPE appeared in the normal cell control wells, but showed CPE in the virus control wells; the results showed that the monoclonal antibody was a specific antibody against FIPV.
[0114] 3.6 Analysis of chromosome number in hybridoma cells
[0115] Normal BALB / c mouse spleen cells have 40 chromosomes, and myeloma cells have 60 to 70 chromosomes, so the number of chromosomes in the fused cells should be between 100 and 110. The test results showed that the number of chromosomes in 3C1 hybridoma cells varied within this range, with an average of 108, which was in line with the expected number.
[0116] 3.7 Results of neutralization titer determination in mouse ascites
[0117] The neutralization titer of ascites FIPV was about 1:5000 as measured by the neutralization test.
[0118] 3.8. Identification of Monoclonal Antibody Purity
[0119] After purification by Protein A affinity chromatography and anion and cation exchange, SDS-PAGE electrophoresis showed that the molecular weight of the heavy chain was about 52 kD and that of the light chain was about 26 kD. Figure 1 .
[0120] Embodiment 2,
[0121] The feline infectious peritonitis virus obtained in Example 1 was used to conduct the following efficacy study:
[0122] 3. Study on the efficacy of monoclonal antibodies against feline infectious peritonitis virus in cats clinically infected with feline infectious peritonitis virus
[0123] 1. Materials
[0124] 1.1. Drugs under investigation
[0125] 3C1 feline infectious peritonitis virus monoclonal antibody injection (neutralizing antibody titer is 1:1024, and the properties, pH value, sterility, mycoplasma, and exogenous virus tests are all qualified) is prepared by this laboratory.
[0126] 1.2 Experimental Animals
[0127] Cats clinically infected with FIPV (if all of the following symptoms are present, they are judged to be clinically infected with FIPV. ① FIPV nucleic acid test is positive; ② white-globulin ratio ≤ 0.5; ③ depression and loss of appetite; ④ effusion in the chest or abdomen) were purchased from multiple cat farms in Hebei and Guangzhou.
[0128] 2. Methods
[0129] 2.1 Grouping
[0130] Ten cats clinically infected with FIPV, 5 cats per group. The first group was treated with monoclonal antibodies, and the second group was treated with adjuvant therapy.
[0131] 2.2 Treatment
[0132] Monoclonal antibody treatment group: After the chest or abdominal accumulation of the test cats was drained by aspiration, 1.0 mL / kg of feline infectious peritonitis virus monoclonal antibody injection was injected intramuscularly, and at the same time, 0.1 ml / kg of Suno was injected subcutaneously, 0.1 ml / kg of vitamin B12 was injected subcutaneously, and 0.1 ml / kg of vitamin B complex was injected subcutaneously, once a day for 10 consecutive days.
[0133] Auxiliary treatment group: After the chest or abdominal accumulation of the test cats was drained by aspiration, 0.1 ml / kg of Suno was injected subcutaneously, 0.1 ml / kg of vitamin B12 was injected subcutaneously, and 0.1 ml / kg of vitamin B complex was injected subcutaneously, once a day for 10 consecutive days.
[0134] 3. Results
[0135] After 7 days of observation, the results were shown in Table 4. The cure rate of cats in the monoclonal antibody treatment group was 60% (3 / 5); the cure rate of cats in the adjuvant treatment group was 0 (0 / 5).
[0136] The cure criteria are: ① White-to-globulin ratio > 0.5; ② Mental state and appetite return to normal; ③ No more fluid accumulation in the chest and abdomen; If all of the above clinical manifestations are met, the patient is considered cured.
[0137] Table 4 Statistical table of treatment status of cats in each group
[0138]
[0139] Note: “T” indicates the number of days of treatment; “ / ” indicates not cured or not dead
[0140] The test results showed that the cure rate of the monoclonal antibody treatment group was 60% higher than that of the adjuvant treatment group, indicating that the feline infectious peritonitis virus monoclonal antibody injection has a good therapeutic effect on cats with clinical infectious peritonitis.
[0141] In the description of this specification, the description of the terms "one embodiment", "some embodiments", "specific embodiments", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.
[0142] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A hybridoma cell line capable of secreting monoclonal antibodies against feline infectious peritonitis virus, characterized in that: The accession number of the hybridoma cell line is CGMCCNO.45347, and the deposit address is the General Microbiology Center of China National Microbiological Culture Collection Administration.
2. A feline infectious peritonitis virus monoclonal antibody, characterized in that: Secreted by the hybridoma cell line of claim 1.
3. A method for preparing a monoclonal antibody against feline infectious peritonitis virus as claimed in claim 2, characterized in that: The steps include: S1, purifying the feline infectious peritonitis virus BJD58 strain and immunizing mice, taking spleen cells of the immunized mice and fusing them with mouse myeloma cells to obtain fusion cells; S2. The fused cells in step S1 are subjected to antibody detection by ELISA method, and cells with positive detection results are the desired hybridoma cells. Then, the hybridoma cells are cloned by limited dilution cloning method and the cell supernatant positivity reaches 100%. Then, the hybridoma cells with positive screening results are expanded and cultured or ascites induction method in syngeneic mice is used to obtain feline infectious peritonitis virus monoclonal antibodies.
4. The method for preparing a monoclonal antibody against feline infectious peritonitis virus according to claim 3, characterized in that: In step S1, the mice are immunized at least once during the process of immunizing the mice with the purified feline infectious peritonitis virus BJD58 strain.
5. The method for preparing a monoclonal antibody against feline infectious peritonitis virus according to claim 3, characterized in that: The mice are immunized at least three times during the process of immunizing the mice with the purified feline infectious peritonitis virus BJD58 strain.
6. The method for preparing a monoclonal antibody against feline infectious peritonitis virus according to any one of claims 3 to 5, characterized in that: The expanded culture method comprises: culturing the hybridoma cells in large quantities by a bioreactor fermentation culture method, then collecting the cultured hybridoma cells for centrifugation, taking the supernatant or concentrating the collected cell supernatant by ultrafiltration; The method of inducing ascites in syngeneic mice is as follows: BALB / c mice weighing more than 20g are selected, and 0.5mL of sterilized liquid paraffin is injected into the peritoneal cavity of each mouse; after 14 to 18 days, hybridoma cells are inoculated into the peritoneal cavity of the mouse; starting from the 7th day after the cell implantation, the abdomen of the mouse is observed every day, and when the abdomen of the mouse is obviously swollen, the abdominal cavity is punctured with a 9# needle to collect ascites, and the ascites is centrifuged at 3000r / min for 10min to remove fat and precipitation, and the supernatant is collected.
7. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the feline infectious peritonitis virus monoclonal antibody according to claim 2 and a pharmaceutically acceptable carrier and / or excipient.
8. The use of the feline infectious peritonitis virus monoclonal antibody as claimed in claim 2 in the preparation of a medical detection preparation, characterized in that: The medical detection preparation is an immunohistochemical detection preparation, an immunofluorescence detection preparation, an immunoblotting reaction detection preparation or an immunoprecipitation detection preparation.
9. A kit for detecting feline infectious peritonitis virus, characterized in that: Comprising the feline infectious peritonitis virus monoclonal antibody as described in claim 2.
10. Use of the feline infectious peritonitis virus monoclonal antibody as claimed in claim 2 in the preparation of a drug for treating feline infectious peritonitis infection.
Citation Information
Cited By
Monoclonal antibody for S protein receptor binding region of feline infectious peritonitis virus and application of monoclonal antibody
CN122145617A
Monoclonal antibody of receptor binding region of feline infectious peritonitis virus s protein and application thereof
CN122145617B
